Sung Ji Nam
Stock Analyst at Scotiabank
(2.82)
# 1,611
Out of 5,152 analysts
83
Total ratings
50.72%
Success rate
6.01%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $92.58 | -35.19% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $55.89 | +34.19% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $202.00 | +36.14% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $518.84 | +13.72% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $128.24 | -2.53% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $27.91 | +43.32% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $15.86 | +152.21% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $5.13 | +16.96% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.13 | +253.98% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.52 | +31.58% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $103.32 | -29.35% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $15.93 | -24.67% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $315.59 | +42.59% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $48.66 | +27.41% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $34.68 | +26.87% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $18.75 | +86.67% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $2.21 | +171.49% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.25 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $92.58
Upside: -35.19%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $55.89
Upside: +34.19%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $202.00
Upside: +36.14%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $518.84
Upside: +13.72%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $128.24
Upside: -2.53%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $27.91
Upside: +43.32%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $15.86
Upside: +152.21%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $5.13
Upside: +16.96%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.13
Upside: +253.98%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.52
Upside: +31.58%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $103.32
Upside: -29.35%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $15.93
Upside: -24.67%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $315.59
Upside: +42.59%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $48.66
Upside: +27.41%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $34.68
Upside: +26.87%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $18.75
Upside: +86.67%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $2.21
Upside: +171.49%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $14.25
Upside: -